Conditions: Acute Lymphoblastic Leukemia
Keywords: B-ALL CD19 MOR208 MOR00208 Xmab5574 B-cell acute lymphoblastic leukemia Fc-optimized Anti-CD19 Antibody
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 22
Healthy volunteers: no

Brief summary:
This is an open-label, multicentre study to characterize the safety and preliminary efficacy of the human anti CD19 antibody MOR00208 in adult subjects with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL)

Detailed description:

Arms:
arm 1: intravenous Infusion of MOR00208, Fc-optimized Anti-CD19 Antibody

Interventions: intervention 1: MOR00208 (formerly Xmab5574)
Intervention descriptions: intervention 1: None

Protocol document: